Skip to main content
Premium Trial:

Request an Annual Quote

Estonian DNA Center to Begin Receiving Samples This Month

NEW YORK, Sept. 9 - A DNA-sample facility jointly run by the Estonian Genome Project Foundation and the California company EGeen is set to receive its first batch of samples this month.


The partners said 10,000 DNA samples collected from three Estonian counties will arrive in the first half of September at the Tartu facility, which opened last week. This initial run will act as the first pancake of the three-year-long EGP project, the partners said. Nationwide collection will follow at an undisclosed time.


EGeen, based in Redwood City, Calif., has exclusive commercial rights to data compiled in the Estonian Genome Project, a government program designed to gather medical data and DNA samples from "a significant portion" of the 1.4 million people who live in this former Soviet-bloc country.


Privately held EGeen said it will use these data for drug and diagnostic discovery.


Click here for more information.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.